Merck & Company Inc (MRK)
U.S. FDA Approves an Additional Indication forCAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease
U.S. FDA Approves an Additional Indication forCAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease
📉 **NEGATIVE** • Medium confidence analysis (67%) • Mild negative signal • Limited downside risk **Sentiment:** Negative (5%) **Content type:** General